These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35569611)

  • 21. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials.
    Mohamed MG; Osman M; Kheiri B; Saleem M; Lacasse A; Alkhouli M
    Int J Cardiol; 2022 Aug; 360():91-98. PubMed ID: 35641323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study.
    Cosin-Sales J; Murcia-Zaragoza JM; Pereyra-Rico HO; la Guía-Galipienso F; Hermans K; Rubio G
    J Comp Eff Res; 2021 Sep; 10(13):975-985. PubMed ID: 34196593
    [No Abstract]   [Full Text] [Related]  

  • 26. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polypill Strategy in Secondary Cardiovascular Prevention.
    Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
    N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scientific development of the CNIC cardiovascular polypill: from conceptualization to clinical efficacy.
    Castellano JM; Fuster V
    Rev Esp Cardiol (Engl Ed); 2023 Dec; 76(12):1055-1060. PubMed ID: 37866619
    [No Abstract]   [Full Text] [Related]  

  • 31. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
    Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
    Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.
    Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C
    Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
    Rao S; Jamal Siddiqi T; Khan MS; Michos ED; Navar AM; Wang TJ; Greene SJ; Prabhakaran D; Khera A; Pandey A
    Prog Cardiovasc Dis; 2022; 73():48-55. PubMed ID: 35114251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease.
    Al-Abdouh A; Mhanna M; Jabri A; Ahmed T; Altibi AM; Ghanem F; Alhuneafat L; Mostafa MR; Abusnina W; Dewaswala N; Bhopalwala H; Kundu A; Michos ED
    Am J Ther; 2024 Mar-Apr 01; 31(2):e193-e195. PubMed ID: 36857708
    [No Abstract]   [Full Text] [Related]  

  • 38. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 39. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
    N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
    N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.